Pneumococcal Vaccine Market Outlook:
Pneumococcal Vaccine Market size was valued at USD 10 billion in 2025 and is projected to reach USD 17.1 billion by the end of 2035, rising at a CAGR of 6.2% during the forecast period, i.e., 2026-2035. In 2026, the industry size of pneumococcal vaccine is assessed at USD 10.6 billion.
The growth of the global market is driven by rising disease incidence rates, expanding government immunization programs, and international health initiatives. Payers are increasingly pressured into negotiating vaccine prices. As per a report by CMS in September 2025, the U.S. Centers for Medicare & Medicaid Services (CMS) reimburses pneumococcal vaccines at 95% of the average wholesale price (AWP) under Medicare Part B. The low uptake rate in at-risk groups and disparities (such as on ethnicity or age) has been motivating research and development of vaccines with broader valency and other delivery technologies. Furthermore, the continued expansion of adult vaccination guidelines has increased the pool of eligible patients, thereby promoting continued demand for this market.
With the perspective of adult vaccination becoming larger and larger, it is simply changing the landscape of the market. According to a report by NLM in January 2024, of 45.6 million adults aged 19 to 64 years existing in the database, 12.5 million adults satisfied the inclusion criteria and thus had at least one qualifying condition, among which most were smokers; others often had chronic lung disease, asthma, or diabetes. After weighting, the total U.S. population of ages from 19 to 64 who were newly eligible for PCVs was estimated at around 56 million. This expansion in patient population will surely boost vaccine uptake, affecting the way health care is planned for and resources allocated. This is a continuously growing consumer base and sustainable demand in the market.
